Skip to main content

James G. Moe

NIH Rank #8640
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 7695503Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2024

Linked Award Amount
$1.5M
Full award amounts, FY2024
Award Records
1
Records listing this PI
Award-Linked Rank
#8,640
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for James G. Moe. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing James G. Moe as a PI. Multi-PI records show the full award amount for context.

  • 5R44AG066384-04R44
    GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD
    $1.5M
    award amount

Award organization

Organizations that administered FY2024 awards listing James G. Moe as a PI.

FY2024 award administered by Oligomerix, Inc (NY).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Oligomerix, Inc
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #8640
  5. 2026
    $2M Cumulative Funding
  6. 2026
    Entered Top 25% Nationally
    Ranked #4021